{
    "2020-10-19": [
        [
            {
                "time": "",
                "original_text": "大参林(603233.SH)拟发行14.05亿元可转债初始转股价83.85元/股",
                "features": {
                    "keywords": [
                        "大参林",
                        "可转债",
                        "发行",
                        "转股价"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药零售"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：冠脉支架国采方案落地 头部企业有望相对受益",
                "features": {
                    "keywords": [
                        "冠脉支架",
                        "国采",
                        "头部企业",
                        "受益"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【兴业固收·转债】华南药品零售连锁领先企业 ——大参转债转债投资价值分析",
                "features": {
                    "keywords": [
                        "大参转债",
                        "投资价值",
                        "药品零售"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药零售"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业报告：持续看好流感及肺炎相关疫苗销售 关注医药三季报业绩主线",
                "features": {
                    "keywords": [
                        "流感",
                        "肺炎",
                        "疫苗",
                        "销售",
                        "三季报",
                        "业绩"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业跨市场周报：冠脉支架全国集采政策落地 未来或催生两大高耗投资方向",
                "features": {
                    "keywords": [
                        "冠脉支架",
                        "全国集采",
                        "政策",
                        "高耗投资"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}